ArticleMolecular and cellular biochemistry2015
MiR-214 regulates the pathogenesis of patients with coronary artery disease by targeting VEGF.
Article in Molecular and cellular biochemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review.Cardiovascular research · 2016Pooled it
- Article
- LncRNA Growth Arrest Specific 5 Promotes Glucose Metabolism Reprogramming Via the IGF2BP1/SIX1 Axis and Inhibits Ferroptosis of Endothelial Progenitor Cells Via the miR-23a-3p/SLC7A11 Axis in Coronary Heart Disease.Anatolian journal of cardiology · 2025Article
- Article
- Epigenetics and Gut Microbiota Crosstalk: A potential Factor in Pathogenesis of Cardiovascular Disorders.Bioengineering (Basel, Switzerland) · 2022Review
- Synthesis, Molecular Docking, and Preclinical Evaluation of a New Succinimide Derivative for Cardioprotective, Hepatoprotective and Lipid-Lowering Effects.Molecules (Basel, Switzerland) · 2022Article
- Study of the Association betweenJournal of personalized medicine · 2022Article
- The miR-199a/214 Cluster Controls Nephrogenesis and Vascularization in a Human Embryonic Stem Cell Model.Stem cell reports · 2021Article
- LncRNA NORAD Promotes Vascular Endothelial Cell Injury and Atherosclerosis Through SuppressingFrontiers in cell and developmental biology · 2021Article
- MicroRNA-214 modulates the senescence of vascular smooth muscle cells in carotid artery stenosis.Molecular medicine (Cambridge, Mass.) · 2020Article
- Noncoding RNAs as Biomarkers for Acute Coronary Syndrome.BioMed research international · 2020Review
- miR-214 Protects Against Uric Acid-Induced Endothelial Cell Apoptosis.Frontiers in medicine · 2020Article
- Extracellular Vesicle miRNAs in the Promotion of Cardiac Neovascularisation.Frontiers in physiology · 2020Review
- miR-214-Dependent Increase of PHLPP2 Levels Mediates the Impairment of Insulin-Stimulated Akt Activation in Mouse Aortic Endothelial Cells Exposed to Methylglyoxal.International journal of molecular sciences · 2018Article
- MicroRNA-378 Promotes Osteogenesis-Angiogenesis Coupling in BMMSCs for Potential Bone Regeneration.Analytical cellular pathology (Amsterdam) · 2018Article
- MicroRNA-199a acts as a potential suppressor of cardiomyocyte autophagy through targetingOncotarget · 2017Article
- A New Network-Based Strategy for Predicting the Potential miRNA-mRNA Interactions in Tumorigenesis.International journal of genomics · 2017Article
- An integrated approach to coronary heart disease diagnosis and clinical management.American journal of translational research · 2017Review
- Article
- Tumor-suppressing roles of miR-214 and miR-218 in breast cancer.Oncology reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating microRNAs (miRNAs) in patient body fluids have recently been considered to hold the potential of being novel disease biomarkers and drug targets. We aimed to investigate the correlation between the levels of circulating miR-214 and the expression of vascular endothelial growth factor (VEGF) in the pathogenesis of coronary heart disease patients to further explore the mechanism involved in the vasculogenesis. Three different cohorts, including 13 acute myocardial infarction patients, 176 angina pectoris patients, and 127 control subjects, were enrolled to investigate the expression levels of circulating miR-214 in patients with myocardial ischemia and also the relationship between plasma miR-214 and severity of coronary stenosis. Plasma miR-214 levels of participants were examined by real-time quantitative PCR. Simultaneously, plasma cardiac troponin I concentrations were measured by ELISA assays. We further detected the correlation of miR-214 and VEGF by molecular and animal assays. MiR-214 was enriched in not only diseased endothelial progenitor cells (EPCs) but also the plasma of coronary artery disease (CAD) patients. Besides, we found out miR-214 was able to suppress VEGF expression and EPC activities. Reporter assays confirmed the direct binding and repression of miR-214 to the 39-UTR of VEGF mRNA. Knockdown of miR-214 not only restored VEGF levels and angiogenic activities of diseased EPCs in vitro, but also further promoted blood flow recovery in ischemic limbs of mice. Circulating miR-214 may be a new biomarker for CAD and as a potential diagnostic tool. And increased miR-214 level may be used to predict the presence and severity of coronary lesions in CAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.